Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00041925 · ClinicalTrials.gov registry record · Phase 2
Prevention of Autogenous Vein Graft Failure in Peripheral Artery Bypass Procedures
A Phase 2 study, sponsored by Anesiva.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,400
- Enrollment target
NCT00041925 is a Phase 2 study that has completed, run by Anesiva. The registered enrollment target is 1,400 participants.
The verdict
NCT00041925, a Phase 2 study, has completed, sponsored by Anesiva.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,400 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the efficacy of graft pretreatment with the E2F decoy, CGT003, as compared to placebo, on the occurrence of graft failure among patients who receive autogenous vein grafts to treat chronic critical limb ischemia; on the occurrence of clinically significant graft stenosis (more than or equal to 70%); and on the incidence of critical limb ischemia (e.g., gangrene, non-healing ischemic ulcers or ischemic rest pain).
Interventions
- DRUG CGT003 (E2F Duplex Decoy)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,400 participants |
| Start Date | 2001-11 |
| Est. Completion | 2004-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00041925
The ClinicalTrials.gov registry entry for NCT00041925 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1,400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Anesiva, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CGT003 (E2F Duplex Decoy) is the first listed.
NCT00041925 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00041925 about?
NCT00041925 is a clinical study titled "Prevention of Autogenous Vein Graft Failure in Peripheral Artery Bypass Procedures". The purpose of this study is to determine the efficacy of graft pretreatment with the E2F decoy, CGT003, as compared to placebo, on the occurrence of graft failure among patients who receive autogenous vein grafts to treat chronic critical limb ischemia; on the occurrence of clinically significant g...
What is the current status of trial NCT00041925?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,400 participants. The study started on 2001-11. Estimated completion is 2004-11.
What interventions are being tested in trial NCT00041925?
The interventions under investigation include: CGT003 (E2F Duplex Decoy) (DRUG).
Who is sponsoring clinical trial NCT00041925?
This trial is sponsored by Anesiva, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.